Azitra (AZTR) Change in Accured Expenses (2022 - 2026)
Azitra's (AZTR) quarterly Change in Accured Expenses came in at $542064.0 in Q1 2026, up 933.44% YoY from $52452.2 in Q1 2025, and up 191.28% on a QoQ basis from -$593872.0 in Q4 2025.
Azitra (AZTR) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Change in Accured Expenses data on file, last reported at $542064.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 933.44% year-over-year to $542064.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106785.0 (up 41.4% YoY) and the FY2025 annual result came in at -$500318.0, down 256.01% from the prior year.
- Change in Accured Expenses grew to $542064.0 in Q1 2026, from -$593872.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $542064.0 in Q1 2026 to a low of -$593872.0 in Q4 2025.
- A 5-year average of $7950.1 and a median of $24845.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 5430.88% — and 2026, when it surged 933.44%.
- Tracing AZTR's Change in Accured Expenses over 5 years: stood at $422616.0 in 2022, then slumped by 82.26% to $74978.0 in 2023, then tumbled by 66.86% to $24845.0 in 2024, then slumped by 2490.31% to -$593872.0 in 2025, then soared by 191.28% to $542064.0 in 2026.
- The last three Change in Accured Expenses figures came in at $542064.0 (Q1 2026), -$593872.0 (Q4 2025), and $53122.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 15,159.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15,159.00 |
| Jun 30, 2026 | 15,159.00 |
| Mar 31, 2026 | 542,064.00 |
| Mar 31, 2026 | 542,064.00 |
| Dec 31, 2025 | -593,872.00 |
| Dec 31, 2025 | -593,872.00 |
| Sep 30, 2025 | 53,122.00 |
| Sep 30, 2025 | 53,122.00 |
| Jun 30, 2025 | 105,471.00 |
| Jun 30, 2025 | 105,471.00 |
| Mar 31, 2025 | -65,039.00 |
| Mar 31, 2025 | -65,039.00 |
| Dec 31, 2024 | 24,845.00 |
| Dec 31, 2024 | 24,845.00 |
| Sep 30, 2024 | -326,143.00 |
| Sep 30, 2024 | -326,143.00 |
| Jun 30, 2024 | 441,859.00 |
| Jun 30, 2024 | 441,859.00 |
| Mar 31, 2024 | -281,096.00 |
| Mar 31, 2024 | -281,096.00 |